GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. West moderates a question & answer session with Drs. Leora Horn and Taofeek OwonikokGreg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

Direct download: GRACEcast-426_AR_2015_QA_Riely_Horn_Acquired_Resistance.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.


Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biospies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.


Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.


Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".


Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recommendations for prophylactic cranial irradiation (PCI).


Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.


Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.


Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.


Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients with a driver mutation and why it occurs.


Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.


Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.


Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.


Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.


Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.


Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.


Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).


As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.


Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.


“Gratitude is one of the most medicinal emotions we can feel.” (Sara Avant Stover) Thank you for joining GRACE in our #LCAM15 activities.

Direct download: GRACEcast-407_LCAM_2015_What_Are_You_Grateful_For.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.

Direct download: GRACEcast-402_LCAM_2015_West_SWOG1400_Lung_MAP.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.

Direct download: GRACEcast-406_LCAM_2015_Camidge_Kadmon_EGFR_Brain_Mets_Trial.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the important things in life. November is Lung Cancer Awareness Month. What are you grateful for?

Direct download: GRACEcast-382_LCAM_2015_Karg_Sickness_Health.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.

Direct download: GRACEcast-404_LCAM_2015_West_Epigenetic_Priming_Immunotherapy.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible. http://bit.ly/UCponatinib


Dr. Seema Nagpal insists on one thing from her lung cancer patients: Proof that they are enjoying their lives. November is Lung Cancer Awareness Month. What are you grateful for?

Direct download: GRACEcast-381_LCAM_2015_Nagpal_Patient_Postcards.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

Direct download: GRACEcast-401_LCAM_2015_West_T790M_Neg_TH4000_Trial.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.


Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.


Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.


Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.


Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.


Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.


Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.


Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.


Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.


Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.


Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.


Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.


Dr. Ben Levy discusses two trials that are trying to determine if immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.


Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival. http://bit.ly/NCIALCHEMIST


ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?


Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.


MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.


Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.


GRACE Founder and President Dr. H. Jack West gives thanks to immunotherapies that offer new hope to his patients. November is Lung Cancer Awareness Month. What are you grateful for?

Direct download: GRACEcast-379_LCAM_2015_West_Celebrates_New_Patient_Options.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.

Direct download: GRACEcast-378_LCAM_2015_November_Lung_Cancer_Awareness_Month.mp4
Category:Lung-Cancer-Video -- posted at: 5:11pm PST

Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.


Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.


Dr. Eddie Garon from UCLA Medical Center reviews the general mechanism of action of immune checkpoint inhibitors and how they can be an effective therapy in lung cancer.


Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.


MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.


Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.


Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.


Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.


Dr. Greg Reily from MSKCC provides an introduction to the epidermal growth factor receptor (EGFR), what an EGFR mutation means, and which patients are more likely to have them.


Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.


Dr. Vivek Mehta, radiation oncologist, reviews the basic principles and treatment approach for limited stage small cell lung cancer, which combines chest radiation with concurrent chemotherapy.


Why radiate a perfectly good brain? Dr. Vivek Mehta, radiation oncologist, discusses the possible role for prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (SCLC) to decrease risk of brain metastases and improve survival.

Direct download: GRACEcast-368_GCVL_LU-GB03_PCI_Extensive_Stage_SCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Radiation to the brain is a component of our treatment of limited stage small cell lung cancer, even with no evidence of cancer there. Dr. Vivek Mehta, radiation oncologist, reviews why we would do such a thing.

Direct download: GRACEcast-367_GCVL_LU-GA02_PCI_Limited_Stage_SCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

Direct download: GRACEcast-366_GCVL_LU-FB04_Avastin_EGFR_TKI_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.

Direct download: GRACEcast-365_GCVL_LU-F11_Maintenance_Therapy_Advanced_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Bronchioloalveolar carcinoma (BAC) is an unusual subtype of lung cancer; medical oncologist Dr. Jack West reviews the evidence on the best systemic therapy to treat advanced, multifocal BAC.

Direct download: GRACEcast-364_GCVL_LU-F08_Optimal_Systemic_BAC_Therapy.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Radiation oncologist Dr. Chris Loiselle reviews the possibility of re-treating with radiation for lung cancer, typically using stereotactic technique, in a previously irradiated field.

Direct download: GRACEcast-363_GCVL_LU-E12_Lung_Cancer_Tumor_Reirradiation.mp4
Category:Lung-Cancer-Video -- posted at: 12:08am PST

Dr. Jack West, medical oncologist/lung cancer specialist, describes special management considerations for indolent lung cancers that may not require treatment or are at risk for "over-treatment."

Direct download: GRACEcast-362_GCVL_LU-F03_Indolent_Lung_Cancer_Management.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Eric Vallieres, thoracic surgeon, introduces us to and provides a brief history for the special case in lung cancer of a "Pancoast Tumor", along with how its optimal treatment has evolved over several decades.

Direct download: GRACEcast-361_GCVL_LU-E06_Pancoast_Tumor_History_Treatment.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. West reviews basic principles of treating locally advanced lung cancer, including the need to treat both local disease and possible distant disease, and the need to balance efficacy with toxicity.

Direct download: GRACEcast-360_GCVL_LU-E02_Locally_Advanced_NSCLC_Management.mp4
Category:Lung-Cancer-Video -- posted at: 4:10pm PST

Thoracic Surgeon Dr. Eric Vallieres reviews the principle of giving chemotherapy prior to lung cancer surgery in order to improve survival and potentially make it possible to do a smaller lung surgery.

Direct download: GRACEcast-359_GCVL_LU-D10_Lung_Cancer_Neoadjuvant_Therapy.mp4
Category:Lung-Cancer-Video -- posted at: 11:59pm PST

Dr. Eric Vallieres, thoracic surgeon, discusses the potential to do smaller lung surgeries on patients with a lung cancer that poses a minimal risk of recurrence.

Direct download: GRACEcast-358_GCVL_LU-D03_Sublobectomy_Surgery_Options.mp4
Category:Lung-Cancer-Video -- posted at: 10:47pm PST

Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis.


The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).


Dr. Chris Loiselle, radiation oncologist, describes stereotactic body radiation therapy (SBRT) as a helpful and increasingly favored treatment option for sicker, "medically inoperable" patients with early stage lung cancer.

Direct download: GRACEcast-355_GCVL_LU-D08_Inoperable_Early_Stage_NSCLC_SBRT.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Should older patients with lung cancer undergo surgery? What issues affect the probability of an elderly patients safely undergoing lung cancer surgery. Dr. Eric Vallières, thoracic surgeon, provides an expert perspective.

Direct download: GRACEcast-354_GCVL_LU-D06_Elderly_LC_Surgery_Considerations.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Eric Vallières, thoracic surgeon, describes the phsycial challenges and risks for patients who undergo a pneumonectomy for lung cancer.

Direct download: GRACEcast-353_GCVL_LU-D05_Pneumonectomy_Surgery_Challenges.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

There are multiple different types of lung cancer surgery. Dr. Eric Vallières, thoracic surgeon, reviews the different forms of lung surgery, include wedge resection, segmentectomy, lobectomy, and pneumonectomy.

Direct download: GRACEcast-352_GCVL_LU-D02_Lung_Cancer_Surgery_Types.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Eric Vallières, thoracic surgeon, reviews the structure and purpose of staging using the current tumor-node-metastasis (TNM) system for lung cancer.

Direct download: GRACEcast-351_GCVL_LU-D01_TNM_Staging_Early_Stage_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 1:20pm PST

Dr. Jed Gorden reviews the technique of pleurodesis to manage the complication of recurrent malignant pleural effusion (MPE).


A tunneled pleural catheter is an excellent way to manage the symptoms of a recurrent malignant pleural effusion. Dr. Jed Gorden describes how it is placed and how it works.

Direct download: GRACEcast-349_GCVL_LU-CC03_Tunneled_Pleural_Catheter.mp4
Category:Lung-Cancer-Video -- posted at: 11:23pm PST

Dr. Jed Gorden describes the details of how a thoracentesis is performed in order to clarify the diagnosis and treat symptoms of a malignant pleural effusion (MPE).


Interventional pulmonologist Dr. Jed Gorden reviews malignant pleural effusions (MPEs) are a common complication of lung cancer and some other cancers.


What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta reviews current practices to minimize risk of cognitive problems.


Radiation therapy can be very helpful in treating painful bone metastases or those at risk for causing a fracture due to compromise of bone strength. Dr. Vivek Mehta reviews the basics of this approach. 


Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood to test for acquired resistance is easier and quicker than needle biopsies. How long until it is standard practice in the US?


A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.

Direct download: GRACEcast-343_ASCO_2015_BRAF_New_Lung_Cancer_Target.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.


Managing brain metastases is a big concern for lung cancer patients. The doctors discuss the drawbacks of whole brain radiotherapy and the fact that there are still unknowns regarding more targeted stereotactic radiosurgery.


A Japanese study of squamous cell carcinoma showed value in nedaplatin vs cisplatin/Taxotere (docetaxel). But with differences in how Asian versus Caucasian patients metabolize chemotherapy, can we presume this benefit would exist for everyone?

Direct download: GRACEcast-340_ASCO_2015_New_Squamous_Cell_NSCLC_Chemotherapy.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

Direct download: GRACEcast-339_ASCO_2015_RET_Lung_Cancer_Next_Big_Target.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.


Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.


The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).

Direct download: GRACEcast-336_ASCO_2015_SCLC_Patients_Immunotherapy_Benefit.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.


Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?


The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?


Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?

Direct download: GRACEcast-332_ASCO_2015_Immunotherapy_Opdivo_Squamous_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 4:39pm PST

Radiation Oncologist Dr. Vivek Mehta reviews the concept of using whole brain radiation for multiple brain metastases, including how it is delivered and risks and benefits of this strategy.

Direct download: GRACEcast-331_GCVL_LU-CA02_WBRT_Brain_Metastases.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West reviews new techniques for evaluating mutations from blood, including detection of circulating tumor cells (CTCs) or mutations in circulating free DNA (cfDNA) that can replace at least some tissue biopsies.

Direct download: GRACEcast-330_GCVL_LU-B10_Liquid_Biopsy_Circulating_Free_DNA.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Unfortunately, there is as much misinformation as good information about the unusual subtupe of lung cancer known as bronchioloalveolar carcinoma (BAC) or adenocarcinoma in situ. Dr. Jack West reviews the top 5 myths.

Direct download: GRACEcast-329_GCVL_LU-AA02_BAC_Myths_Misconceptions.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Bronchioloalveolar carcinoma (BAC), also known as adenocarcinoma in situ, is an unusual subtype of lung cancer with its own appearance under a microscope and on imaging. Dr. Jack West introduces some of the basics of the unique features of BAC.

Direct download: GRACEcast-328_GCVL_LU-AA01_Bronchioloalveolar_Carcinoma_BAC.mp4
Category:Lung-Cancer-Video -- posted at: 10:59pm PST

Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.